Eli Lilly Halts Rheumatoid Arthritis Drug Development

It will take a first-quarter charge after stopping the research

   

prescription drugs 300x180 Eli Lilly Halts Rheumatoid Arthritis Drug DevelopmentPoor results from a late-stage trial has prompted Eli Lilly (NYSE:LLY) to abandon further research on a potential treatment for rheumatoid arthritis.

The company said testing of tabalumab in patients experiencing moderate to severe rheumatoid arthritis showed that the drug did not significantly improve their condition. Lilly will take a $50 million charge during the first quarter for stopping the drug’s development, Reuters noted.

MerckLogo e1282588089406 Eli Lilly Halts Rheumatoid Arthritis Drug Development
Merck Tumbles on Drug Worries

More than 1.3 million Americans suffer from rheumatoid arthritis, which causes painful joint and tissue inflammation.

While Lilly will no longer pursue tabalumab for rheumatoid arthritis, the drug will continue in clinical trials for the treatment of systemic lupus erythematosus and multiple myeloma.

Shares of Eli Lilly fell about 1% in Thursday morning trading.


Article printed from InvestorPlace Media, http://investorplace.com/2013/02/eli-lilly-halts-rheumatoid-arthritis-drug-development/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.